Compare UHS & RGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UHS | RGC |
|---|---|---|
| Founded | 1978 | 2014 |
| Country | United States | Hong Kong |
| Employees | N/A | N/A |
| Industry | Hospital/Nursing Management | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.4B | 11.5B |
| IPO Year | 1994 | 2020 |
| Metric | UHS | RGC |
|---|---|---|
| Price | $167.68 | $29.37 |
| Analyst Decision | Buy | |
| Analyst Count | 11 | 0 |
| Target Price | ★ $216.36 | N/A |
| AVG Volume (30 Days) | ★ 624.0K | 157.0K |
| Earning Date | 04-27-2026 | 10-31-2025 |
| Dividend Yield | ★ 0.48% | N/A |
| EPS Growth | ★ 37.34 | N/A |
| EPS | ★ 23.10 | N/A |
| Revenue | ★ $17,364,829,000.00 | N/A |
| Revenue This Year | $7.67 | N/A |
| Revenue Next Year | $4.99 | N/A |
| P/E Ratio | $7.28 | ★ N/A |
| Revenue Growth | ★ 9.71 | N/A |
| 52 Week Low | $152.33 | $9.39 |
| 52 Week High | $246.33 | $950.00 |
| Indicator | UHS | RGC |
|---|---|---|
| Relative Strength Index (RSI) | 37.18 | 53.31 |
| Support Level | $152.33 | $21.81 |
| Resistance Level | $169.65 | $36.75 |
| Average True Range (ATR) | 6.38 | 2.16 |
| MACD | -0.79 | -0.11 |
| Stochastic Oscillator | 35.26 | 42.35 |
Universal Health Services primarily offers healthcare services through its behavioral health centers, acute care hospitals, and related outpatient facilities. As of late 2025, the company operated 346 inpatient behavioral health centers, 29 acute care hospitals, and many supportive outpatient facilities. Its operations are concentrated in the US, particularly in Nevada (21% of 2025 operating profits), Texas (19%), and California (13%), although it does have some exposure to the UK behavioral health market (6% of 2025 sales) too. While its acute care services account for over 55% of revenue, the behavioral health centers sport higher margins and account for over 55% of pretax profits.
Regencell Bioscience Holdings Ltd is a bioscience company focusing on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degenerations, specifically ADHD and ASD, and infectious diseases affecting people's immune systems.